systemic sclerosis

Mirodenafil is a PDE-5 inhibitor developed for the treatment of erectile dysfunction.

Mirodenafil dihydrochloride is a PDE-5 inhibitor developed for the treatment of erectile dysfunction.

DZ2002, an orally active, reversible, and low-cytotoxic type III SAHH inhibitor (Ki=17.9 nM), exhibits significant immunosuppressive activity. It effectively prevents experimental dermal fibrosis by reversing the profibrotic phenotype in multiple cell types, making it useful for studying autoimmune diseases like lupus syndrome and systemic sclerosis.

Aminaftone, a derivative of 4-aminobenzoic acid, inhibits endothelin-1 (ET-1) production and is used to study hypertension and systemic sclerosis.

Ketanserin tartrate (KJK-945 tartrate) is a 5-HT2A receptor and α1-adrenergic receptor antagonist with antihypertensive activity, inhibits serotonin-induced vasoconstriction and platelet activation, and can be used in the study of systemic sclerosis.

ALK5-IN-28 is a selective inhibitor of ALK-5 with an IC50 ≤ 10 nM that inhibits TGF-β-induced SMAD signalling.ALK5-IN-28 has the potential to inhibit tumour growth in vivo.ALK5-IN-28 can be used to study proliferative diseases (e.g. cancer, fibrotic diseases, systemic sclerosis).

ALK5-IN-31 is a selective inhibitor of ALK-5 (IC50≤10 nM) and also inhibits TGF-β-induced SMAD signalling.ALK5-IN-31 has the potential to inhibit tumour growth in vivo.ALK5-IN-31 can be used in the study of proliferative diseases (e.g. cancer, fibrotic diseases, systemic sclerosis).

ALK5-IN-32 is a selective inhibitor of ALK-5 (10 nMsystemic sclerosis). .

SGC agonist 2 is a potent soluble guanylate cyclase (SGC) agonist with potential therapeutic applications for cardiovascular diseases (heart failure, angina, pulmonary hypertension, myocardial infarction) and fibrotic diseases (renal fibrosis, systemic sclerosis).

PAD-IN-2 is a potent inhibitor of pad4 with an IC50 value <1 μM and can be used to study autoimmune diseases and cancers such as rheumatoid arthritis, vasculitis, systemic lupus erythematosus, cutaneous lupus erythematosus, cystic fibrosis, ulcerative colitis, asthma, multiple sclerosis, and psoriasis.

Metelimumab (CAT-192) is a humanised monoclonal antibody targeting TGFβ1, which can be used to study diffuse systemic sclerosis (d-SSc).

Frexalimab (SAR441344) is a second-generation humanized monoclonal antibody targeting CD40L. It blocks the CD40/CD40L signaling pathway to reduce inflammation and tissue damage, making it applicable for autoimmune diseases such as primary Sjögren's syndrome, systemic lupus erythematosus, and multiple sclerosis.

Atacicept (TACI-Ig) is a homodimeric fusion protein that inhibits B-cell stimulation by binding to B-lymphocyte stimulatory factors and proliferation-inducing ligands, and can be used in the study of systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, multiple sclerosis, and various B-cell malignancies.

Anti-CXCL4/PF4 Antibody is a humanized monoclonal antibody that binds specifically to the chemokine CXCL4 (PF4) with high affinity. By blocking its mediated biological effects and receptor interactions, it inhibits fibroblast activation and pro-inflammatory signaling. It serves as an important pharmacological tool for researching systemic sclerosis, thrombotic disorders, and inflammatory immune responses.

RTX-002 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. This compound is applicable in the research of autoimmune diseases such as systemic lupus erythematosus and multiple sclerosis.

AX-202 is a human monoclonal antibody (mAb) that targets S100A4. It exhibits antifibrotic properties in the Tsk-1 mouse model. AX-202 can be utilized for research on plaque psoriasis and systemic sclerosis.

GSK-2330811 is a humanized IgG1 antibody targeting oncostatin M (OSM). It holds potential for studying diffuse systemic sclerosis. For the isotype control of GSK-2330811, refer to Human IgG1 kappa, Isotype Control.